Advertisement

Proteins Encoded by the Human T-Lymphotropic Virus Type III/ Lymphadenopathy Associated Virus (HTLV-III/LAV) Genes

  • M. G. Sarngadharan
  • Fulvia diMarzo Veronese
  • Robert C. Gallo
Part of the NATO ASI Series book series (NSSA, volume 120)

Abstract

Human T-lymphotropic virus-type III/lymphadenopathy associated virus (HTLV-III/LAV) has been identified as the primary etiologic agent of human acquired immune deficiency syndrome (AIDS) (1–4). Among members of epidemiologically identified risk groups of AIDS, there has been a high prevalence of HTLV-III/LAV infection irrespective of whether they have clinical AIDS or have only some signs and symptoms associated with AIDS [AIDS-related complex (ARC)], or are completely free of any disease symptoms (4–6). Thus a significant proportion (up to 50 or 60 %), depending on where they live) of homosexual males at risk for AIDS have serum antibodies to HTLV-III/LAV proteins (6,7). Infectious virus has been isolated from lymphocyte cultures derived from many of these asymptomatic antibody-positive individuals (2,8). HTLV-III/LAV-infection through contaminated blood has been identified as the cause of AIDS in transfusion recipients with no other risk factor for AIDS (9,10).

Keywords

Acquire Immune Deficiency Syndrome Bovine Leukemia Virus Equine Infectious Anemia Virus Acquire Immune Deficiency Syndrome Patient Acquire Immune Deficiency Syndrome Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M.Popovic, M.G. Sarngadharan, E. Read, and R.C. Gallo, Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science, 224: 497–500 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    R.C. Gallo, S.Z. Salahuddin, M. Popovic, G.M. Shearer, M. Kaplan, B.F. Haynes, T.J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P.D. Markham, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 224: 500–503 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    F.Barre-Sinoussi, J.-C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, F. Axler-Bline, F. Brun-Vezinet, C. Rouzioux, W. Rozenbaum, and L. Montagnier, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220: 868–871 (1983).CrossRefGoogle Scholar
  4. 4.
    M.G. Sarngadharan, M. Popovic, L. Bruch, J. Schuepbach, and R.C. Gallo, Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science, 224: 506–508 (1984).PubMedCrossRefGoogle Scholar
  5. 5.
    B.Safai, M.G. Sarngadharan, J.E. Groopman, K. Arnett, M. Popovic, A. Sliski, J. Schuepbach, and R.C. Gallo, Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet, i: 1438–1440 (1984).Google Scholar
  6. 6.
    M.G. Sarngadharan, P.D. Markham, and R.C. Gallo, Human T-cell leukemia viruses, in: “Virology” (B.N. Fields, D.M. Knipe, R.M. Chanock, J.L. Melnick, and R.E. Shope, Eds.), Raven Press, New York, pp. 1345–1371 (1985).Google Scholar
  7. 7.
    J.E. Groopman, K.H. Mayer, M.G. Sarngadharan, D. Ayotte, A.L. DeVico, R. Finberg, A.H. Sliski, J.D. Allan, and R.C. Gallo, Seroepidemiology of HTLV-III among homosexual men with acquired immunodeficiency syndrome, generalized lymphadenopathy and asymptomatic case controls in Boston. Ann. Int. Med., 102: 334–337 (1985).PubMedGoogle Scholar
  8. 8.
    S.Z. Salahuddin, P.D. Markham, M. Popovic, M.G. Sarngadharan, S. Orndorff, A. Fladagar, A. Patel, J. Gold, and R.C. Gallo, Isolation of infectious T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers. A Study of risk groups and tissue sources. Proc. Natl. Acad. Sci. USA, 82: 5530–5534 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    J.E. Groopman, S.Z. Salahuddin, M.G. Sarngadharan, J.I. Mullins, J.L. Sullivan, C. Mulder, C.J. O’Hara, S.H. Cheeseman, H. Haverkos, P. Forgacs, N. Riedel, M.F. McLane, M. Essex, and R.C. Gallo, Virologic studies in a case of transfusion-associated AIDS. N.Engl. J. Med., 311: 1419–1422 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    H.W. Jaffe, M.G. Sarngadharan, A.L. DeVico, L. Bruch, J.P. Getchell, V.S. Kalyanaraman, H.W. Harverkos, R.L. Stoneburner, R.C. Gallo, and J.W. Curran, Infection with HTLV-III/LAV and transfusion-associated acquired immunodeficiency syndrome. J. Amer. Med. Assoc. 253: 770–773 (1985).CrossRefGoogle Scholar
  11. 11.
    J.E. Groopman, M.G. Sarngadharan, S.Z. Salahuddin, R. Buxbaum, M.S. Huberman, J. Kinniburgh, A. Sliski, M.F. McLane, M. Essex, and R.C. Gallo, Apparent transmission of human T-cell leukemia virus type III to a heterosexual women with the acquired immunodeficiency syndrome. Ann. Int. Med., 102: 63–66 (1985).PubMedGoogle Scholar
  12. 12.
    L.Ratner, W. Haseltine, R. Patarca, K.J. Livak, B. Starcich, S.F. Josephs, E.R. Doran, J.A. Rafalski, E.A. Whitehorn, K. Baumeister, L. Ivanoff, S.R. Petteway, M.L. Pearson, J.A. Lautenberger, T.S. Papas, J. Ghrayeb, N.T. Chang, R.C. Gallo, and F. Wong-Staal, Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, 313: 277–284 (1985).CrossRefGoogle Scholar
  13. 13.
    S.K. Arya, C. Guo, S.F. Josephs, and F. Wong-Staal, Trans-activator gene of human T-lymphotropic virus type III (HTLV-III), Science, 229: 69–73 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    J.Sodroski, R. Patarca, C. Rosen, F. Wong-Staal, and W. Haseltine, Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science, 229: 74–77 (1985).CrossRefGoogle Scholar
  15. 15.
    M.G. Sarngadharan, L. Bruch, M. Popovic, and R.C. Gallo, Immunological properties of the gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III). Proc. Natl. Acad. Sci. USA, 82: 3481–3484 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    V.S. Kalyanaraman, C.D. Cabradilla, J.P. Getchell, R. Narayanan, E.H. Braff, J.-C. Chermann, F. Barre-Sinoussi, L. Montagnier, T.J. Spira, J. Kaplan, D. Fishbein, H.W. Jaffe, J.W. Curran, and D.P. Francis, Antibodies to the core protein of lymphadenopathyassociated virus (LAV) in patients with AIDS. Science, 225: 321–323 (1984).PubMedCrossRefGoogle Scholar
  17. 17.
    V.S. Kalyanaraman, M. Jarvis-Morar, M.G. Sarngadharan, and R.C.Gallo, Immunological characterization of the low molecular weight gag gene products p19 and p15 of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of human neutral antibodies to them. Virology, 132: 61–70 (1984).Google Scholar
  18. 18.
    F.D. Veronese, M.G. Sarngadharan, R. Rahman, P.D. Markham, M. Popovic, A.J. Bodner, and R.C. Gallo, Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. Proc. Natl. Acad. Sci. USA, 82: 5199–5202 (1985).CrossRefGoogle Scholar
  19. 19.
    A.M. Schultz, and S. Oroszlan, In vivo modification of retroviral gag gene-encoded polyproteins by myristic acid. J. Virol., 46: 355–361 (1983).Google Scholar
  20. 20.
    S.Oroszlan, T.D. Copeland, V.S. Kalyanaraman, M.G. Sarngadharan, A.M. Schultz, and R.C. Gallo, Chemical analysis of human T-cell leukemia virus structural proteins. In: “Human T-Cell Leukemia/ Lymphoma Virus” (R.C. Gallo, M. Essex, and L. Gross, Eds.) Cold Spring Harbor Laboratory, New York, pp. 91–100 (1984).Google Scholar
  21. 21.
    A.Chandra, T. Gerber, and P. Chandra, Biochemical heterogeneity of reverse transcriptase purified from the AIDS virus, HTLV-III. FEBS Letters, 197: 84–88 (1986).CrossRefGoogle Scholar
  22. 22.
    F.D. Veronese, T.D. Copeland, A.L. DeVico, R. Rahman, S. Orszlan, R.C. Gallo, and M.G. Sarngadharan, Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science, 231: 1289–1291 (1986).CrossRefGoogle Scholar
  23. 23.
    A.Chandra, T. Gerber, S. Kaul, C. Wolf, I. Demirhan, and P. Chandra, Serological relationship between reverse transcriptases from human T-cell lymphotropic viruses defined by monoclonal antibodies. FEBS Letters, 200: 327–332 (1986).CrossRefGoogle Scholar
  24. 24.
    D.P. Grandgenett, G.F. Gerard, and M. Green, A single subunit from avian myeloblastosis virus with both RNA-directed DNA polymerase and ribonuclease H activity. Proc. Natl. Acad. Sci. USA, 70: 230–234 (1973).PubMedCrossRefGoogle Scholar
  25. 25.
    G.F. Gerard, and D. P. Grandgenett, Purification and characterization of the DNA polymerase and RNAse H activities in Moloney murine sarcoma-leukemia virus. J. Virol., 15: 785–797 (1975).PubMedGoogle Scholar
  26. 26.
    K.S. Steimer, K.W. Higgins, M.A. Powers, J.C. Stephans, Y. Gyenes, C. George-Nascimento, P.A. Luciw, P.J. Barr, R.A. Hallewell, and R. Sanchez-Pescador, Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals. J. Virol., 58: 9–16 (1986).PubMedGoogle Scholar
  27. 27.
    L.W. Kitchen, F. Garin, J.L. Sullivan, M.F. McLane, D.B. Brettler, P.H.Levine, and M. Essex, Aetiology of AIDS-antibodies to human T-cell leukemia virus (type III) in haemophiliacs. Nature, 312: 367–369 (1984).PubMedCrossRefGoogle Scholar
  28. 28.
    F.D. Veronese, A.L. DeVico, T.D. Copeland, S. Oroszlan, R.C. Gallo, and M.G. Sarngadharan, Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science, 229: 1402–1405 (1985).PubMedCrossRefGoogle Scholar
  29. 29.
    M.G. Sarngadharan, F.D. Veronese, S. Lee, and R.C. Gallo, Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS related complex and of asymptomatic carriers of HTLV-III infection. Cancer Res., 45: 4574s - 4577s (1985)PubMedGoogle Scholar
  30. 30.
    J.S. Allan, J.E. Colligan, F. Barin, M.F. McLane, J.G. Sodroski, C.A. Rosen, W.A. Haseltine, T.H. Lee, and M. Essex, Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science, 228, 1091–1094 (1985).PubMedCrossRefGoogle Scholar
  31. 31.
    D.P. Bolognesi, R.C. Montelaro, H. Frank, and W. Schaefer, Assembly of type C oncornaviruses: A model. Science, 199: 183–186 (1978).PubMedCrossRefGoogle Scholar
  32. 32.
    S.K. Arya, and R.C. Gallo, Three novel genes of human T-lymphotropic virus type III: Immune reactivity of their products with sera from acquired immune deficiency syndrome patients. Proc. Natl. Acad. Scie. USA, 83: 2209–2213 (1986).CrossRefGoogle Scholar
  33. 33.
    N.Manca, F.D. Veronese, D.D. Ho, M.G. Sarngadharan, and R.C. Gallo, Variable immunological anti-viral profiles in sera from HTLV-IIIinfected patients, submitted for publication.Google Scholar
  34. 34.
    J.G. Sodroski, C.A. Rosen, and W.A. Haseltine, Trans-acting transcriptional activation of the long terminal repeat of human T-lymphotorpic viruses in infected cells. Science, 225: 381–385 (1986).CrossRefGoogle Scholar
  35. 35.
    C.A. Rosen, J.G. Sodroski, R. Kettman, A. Burny, and W.A. Haseltine, Transactivation of the bovine leukemia virus long terminal repeat in BLV-infected cells. Science, 227, 320–322 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • M. G. Sarngadharan
    • 1
  • Fulvia diMarzo Veronese
    • 1
  • Robert C. Gallo
    • 2
  1. 1.Department of Cell BiologyBionetics Research, Inc.RockvilleUSA
  2. 2.Laboratory of Tumor Cell BiologyNational Cancer InstituteBethesdaUSA

Personalised recommendations